Press release
Uveitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2024-2034), Investigates DelveInsight | Tarsier Pharma, Roche, Eli Lilly and Company, Oculis, Acelyrin/ Affibody Medical
DelveInsight's "Uveitis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Uveitis, historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Uveitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Uveitis Market Forecast [https://www.delveinsight.com/sample-request/uveitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Uveitis Market Report:
*
The Uveitis market size was valued approximately USD 1,544 Million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In 2023, the United States held the largest market share for uveitis, with a value of approximately USD 813.44 million, surpassing the combined market sizes of the EU4 countries (Germany, Italy, France, and Spain), the UK, and Japan.
*
Within the EU4 and the UK, Germany boasted the highest market size, reaching around USD 118.28 million in 2023. Projections suggest this figure will rise further, with Germany anticipated to lead the market followed by the UK and France by 2034.
*
According to DelveInsight analysis, approximately 1 million diagnosed prevalent cases of uveitis were identified in the 7MM in 2023. This figure is anticipated to rise over the study period from 2020 to 2034.
*
Based on DelveInsight's analysis, the United States contributed the largest share, approximately 38%, of the total diagnosed prevalent cases of uveitis in the 7MM in 2023. It is projected that these cases will continue to rise by 2034.
*
In the United States, it was estimated that in 2023 there were around 34,351 cases of infectious uveitis and noninfectious uveitis, respectively. These figures are anticipated to undergo changes during the forecast period from 2024 to 2034.
*
In 2023, Japan reported roughly 214,000 diagnosed prevalent cases of uveitis. According to DelveInsight's analysis, these diagnosed prevalent cases are projected to decline by 2034.
*
Key Uveitis Companies: Tarsier Pharma, Oculis Pharma, Roche/Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin/Affibody Medical, Priovant Therapeutics (Roivant Sciences and Pfizer), Clearside Biomedical, Inc., Eli Lilly and Company, ACELYRIN Inc., AbbVie, National Eye Institute, AbbVie, Massachusetts Eye Research, Priovant Therapeutics, Inc., Alumis Inc, Quan Dong Nguyen, Soligenix, Ganzhou Hemay Pharmaceutical, Amgen, and others
*
Key Uveitis Therapies: TRS01, Licaminlimab (OCS-02), Vamikibart (RO720220/RG6179), OLUMIANT (baricitinib), EYS606, Izokibep, Brepocitinib, QLETLI, Bio-Thera Solutios, triamcinolone acetonide (Triesence Registered ), Baricitinib, Izokibep, Adalimumab, B27PD, adalimumab, Ixekizumab Prefilled Syringe, Brepocitinib, ESK-001, OCS-01, Dusquetide, Hemay005, Apremilast, and others
*
The Uveitis epidemiology based on gender analyzed that noninfectious uveitis cases are higher in number than infectious uveitis cases
*
The Uveitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Uveitis pipeline products will significantly revolutionize the Uveitis market dynamics.
Uveitis Overview
Uveitis is a condition characterized by inflammation of the uvea, which is the middle layer of the eye. The uvea consists of the iris, ciliary body, and choroid, and inflammation can affect one or more of these structures. Uveitis can be acute or chronic and may involve one or both eyes.
Get a Free sample for the Uveitis Market Report:
https://www.delveinsight.com/report-store/uveitis-market [https://www.delveinsight.com/report-store/uveitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Uveitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Uveitis Epidemiology Segmentation:
The Uveitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Uveitis
*
Prevalent Cases of Uveitis by severity
*
Gender-specific Prevalence of Uveitis
*
Diagnosed Cases of Episodic and Chronic Uveitis
Download the report to understand which factors are driving Uveitis epidemiology trends @ Uveitis Epidemiology Forecast [https://www.delveinsight.com/sample-request/uveitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Uveitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Uveitis market or expected to get launched during the study period. The analysis covers Uveitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Uveitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Uveitis Therapies and Key Companies
*
TRS01: Tarsier Pharma
*
Licaminlimab (OCS-02): Oculis Pharma
*
Vamikibart (RO720220/RG6179): Roche/Eleven Biotherapeutics
*
OLUMIANT (baricitinib): Eli Lilly and Company
*
EYS606: Eyevensys
*
Izokibep: Acelyrin/Affibody Medical
*
Brepocitinib: Priovant Therapeutics (Roivant Sciences and Pfizer)
*
QLETLI: Bio-Thera Solutions
*
triamcinolone acetonide (Triesence Registered ): Clearside Biomedical, Inc.
*
Baricitinib: Eli Lilly and Company
*
Izokibep: ACELYRIN Inc.
*
Adalimumab: AbbVie
*
B27PD: National Eye Institute
*
adalimumab: AbbVie
*
Ixekizumab Prefilled Syringe: Massachusetts Eye Research
*
Brepocitinib: Priovant Therapeutics, Inc.
*
ESK-001: Alumis Inc
*
OCS-01: Quan Dong Nguyen
*
Dusquetide: Soligenix
*
Hemay005: Ganzhou Hemay Pharmaceutical
*
Apremilast: Amgen
Discover more about therapies set to grab major Uveitis market share @ Uveitis Treatment Market [https://www.delveinsight.com/sample-request/uveitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Uveitis Market Strengths
*
The remarkable advances in ocular immunology over the past decades have led to a better understanding of the molecular mechanisms that underlie etiology and susceptibility to uveitis
*
New drugs with diverse mechanisms of action and routes of administration have been approved in the recent past, improving the treatment regime
Uveitis Market Opportunities
*
Opportunity for companies to implement knowledge from recent advances in understanding the etiologies associated with uveitis to evaluate potential drugs with novel targets
*
Biomarker discovery and proteomics provide potential targets for therapeutic intervention by the drugs that are available and accessible, besides providing information about the drug that can be avoided
Scope of the Uveitis Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Uveitis Companies: Tarsier Pharma, Oculis Pharma, Roche/Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin/Affibody Medical, Priovant Therapeutics (Roivant Sciences and Pfizer), Clearside Biomedical, Inc., Eli Lilly and Company, ACELYRIN Inc., AbbVie, National Eye Institute, AbbVie, Massachusetts Eye Research, Priovant Therapeutics, Inc., Alumis Inc, Quan Dong Nguyen, Soligenix, Ganzhou Hemay Pharmaceutical, Amgen, and others
*
Key Uveitis Therapies: TRS01, Licaminlimab (OCS-02), Vamikibart (RO720220/RG6179), OLUMIANT (baricitinib), EYS606, Izokibep, Brepocitinib, QLETLI, Bio-Thera Solutios, triamcinolone acetonide (Triesence Registered ), Baricitinib, Izokibep, Adalimumab, B27PD, adalimumab, Ixekizumab Prefilled Syringe, Brepocitinib, ESK-001, OCS-01, Dusquetide, Hemay005, Apremilast, and others
*
Uveitis Therapeutic Assessment: Uveitis current marketed and Uveitis emerging therapies
*
Uveitis Market Dynamics: Uveitis market drivers and Uveitis market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Uveitis Unmet Needs, KOL's views, Analyst's views, Uveitis Market Access and Reimbursement
To know more about Uveitis companies working in the treatment market, visit @ Uveitis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/uveitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Uveitis Market Report Introduction
2. Executive Summary for Uveitis
3. SWOT analysis of Uveitis
4. Uveitis Patient Share (%) Overview at a Glance
5. Uveitis Market Overview at a Glance
6. Uveitis Disease Background and Overview
7. Uveitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Uveitis
9. Uveitis Current Treatment and Medical Practices
10. Uveitis Unmet Needs
11. Uveitis Emerging Therapies
12. Uveitis Market Outlook
13. Country-Wise Uveitis Market Analysis (2020-2034)
14. Uveitis Market Access and Reimbursement of Therapies
15. Uveitis Market Drivers
16. Uveitis Market Barriers
17. Uveitis Appendix
18. Uveitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=uveitis-market-to-exhibit-rapid-growth-rate-during-the-forecast-period-20242034-investigates-delveinsight-tarsier-pharma-roche-eli-lilly-and-company-oculis-acelyrin-affibody-medical]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uveitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2024-2034), Investigates DelveInsight | Tarsier Pharma, Roche, Eli Lilly and Company, Oculis, Acelyrin/ Affibody Medical here
News-ID: 3484341 • Views: …
More Releases from ABNewswire
Author's Tranquility Press Announces the Release of "Nature's Child: Healing Chi …
A Revolutionary Guide to Holistic Health for Children
Author's Tranquility Press proudly announces the release of "Nature's Child: Healing Children from the Inside Out [https://www.amazon.com/Natures-Child-Healing-Children-Inside/dp/1963636295/ref=monarch_sidesheet]" by Paula J Johnson. This transformative book offers parents a comprehensive and natural approach to managing children's health issues, aiming to address the root causes of sickness while strengthening the immune system. Now available on Amazon, "Nature's Child" is an essential resource for parents seeking safe,…
Manhattan Grand Larceny Attorney Russ Kofman Releases Insightful Article on Diff …
Manhattan grand larceny attorney Russ Kofman (https://www.lebedinkofman.com/extortion-vs-blackmail/), of Lebedin Kofman LLP, has recently published an educational article titled "Extortion Vs. Blackmail." This detailed piece sheds light on the legal distinctions and implications of these two serious offenses under New York law, providing crucial information for individuals facing such charges.
In his article, the Manhattan grand larceny attorney explains that both extortion and blackmail involve coercion, but they differ significantly in how…
Brooklyn Slip and Fall Lawyer Samantha Kucher Publishes Insightful Article on th …
Brooklyn slip and fall lawyer Samantha Kucher (https://www.rrklawgroup.com/should-i-get-a-lawyer-for-a-slip-and-fall/) of Kucher Law Group has recently released an essential article titled "Should I Get A Lawyer For A Slip And Fall?" which provides valuable insights into the necessity of professional legal assistance in slip and fall cases. This article is a must-read for anyone who has experienced such an incident or knows someone who has.
Slip and fall accidents can occur unexpectedly and…
Combining Laser Hair Removal with Tattoo Removal - Comprehensive Aesthetic Solut …
Combining laser hair removal with tattoo removal offers individuals a comprehensive solution for addressing multiple aesthetic concerns in a single treatment session.
In the realm of aesthetic treatments, the combination of laser hair removal and tattoo removal offers a comprehensive solution for individuals seeking to enhance their appearance and achieve their desired aesthetic goals.
While laser hair removal targets unwanted hair follicles, tattoo removal focuses on eliminating unwanted ink from the skin,…
More Releases for Uveitis
Japan Industry Statistics of Uveitis Treatment
Global Uveitis Treatment Market: Overview
Uveitis, an autoimmune eye disease, is considered rare for just around 38 in 100,000 people are afflicted by it. Because of this, it is often overlooked. Patients afflicted by uveitis are often referred to an expert after much delay on account of less awareness about the eye malady. This delays timely diagnosis and results in irreversible damage to various ocular structures.
Read Report Overview: https://www.transparencymarketresearch.com/uveitis-treatment-market.html
As per Cochrane,…
Uveitis Treatment Market Analysis of Top industry Scenario
Global Uveitis Treatment Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables).
According to a new report published by Allied Market Research, titled, "Uveitis Treatment Market by Drug Class (Anti-inflammatory, Antimicrobial Drugs, Immunotherapy &…
Uveitis Treatment Market: Global Market Of Uveitis Disease Is Estimated To Reach …
Uveitis Treatment Market
Precision Business Insights (PBI) in its report titled “Global Uveitis Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2017 and Forecast 2018-2027” assesses the market performance over 2018-2027. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
Uveitis is swelling of the middle layer of the eye,…
Uveitis Therapeutic and Disease Pipeline Review H1
Summary
Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or…
Anterior Uveitis Market: An Industry Case Study
Uveitis is the inflammation of the uveal region of the eye, most commonly by an infection. Uvea is a group of pigmented and non pigmented tissues lying in the middle among the three layers that make the eye. Uvea again consists of three layers: iris, cilliary body and the choroid. The uvea is also known as the uveal tract in some medical circles, this tract is necessary for the nutrition…
Uveitis Treatment Market By Indication (Anterior uveitis, Intermediate uveitis, …
Uveitis is a combined condition of inflammation and swelling of the eyes. Uvea comprises of three parts Iris, ciliary body (small ring shape muscles behind iris and choroid), and choroid (it is the layer of tissue between retina and sclera), which decides eye color and helps eye in focusing and absorbing light. Uveitis can be caused by eye problems, autoimmune disease, HIV, multiple sclerosis, reactive arthritis, Kawasaki disease tuberculosis, and…
